Atossa Therapeutics Faces Delisting Concerns

Ticker: ATOS · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1488039

Atossa Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtossa Therapeutics, INC. (ATOS)
Form Type8-K
Filed DateFeb 24, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

Atossa might get delisted - stock exchange rules are a problem.

AI Summary

Atossa Therapeutics, Inc. filed an 8-K on February 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of February 21, 2025. The company, incorporated in Delaware, is based in Seattle, Washington.

Why It Matters

This filing indicates potential issues with Atossa Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.

Key Players & Entities

FAQ

What specific listing rule or standard has Atossa Therapeutics failed to satisfy?

The filing does not specify the exact rule or standard that Atossa Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

When was the earliest event reported that led to this notice?

The earliest event reported was on February 21, 2025.

What is Atossa Therapeutics' principal executive office address?

The principal executive offices are located at 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number for Atossa Therapeutics, Inc. is 26-4753208.

Has the company's name changed previously?

Yes, the company was formerly known as Atossa Genetics Inc., with a date of name change on March 25, 2010.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding ATOSSA THERAPEUTICS, INC. (ATOS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing